These findings demonstrate that the synergy between LSPA-mediated radiosensitization and PARP inhibition transforms dying tumor cells into a powerful in situ vaccine, thereby robustly activating STING-dependent antitumor immunity. The gene discussed is STING1; the disease is neoplasm.